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Abstract
Background: Stat3 is a cytokine- and growth factor-inducible transcription factor that regulates cell motility,
migration, and invasion under normal and pathological situations, making it a promising target for cancer
therapeutics. The hepatocyte growth factor (HGF)/c-met receptor tyrosine kinase signaling pathway is responsible
for stimulation of cell motility and invasion, and Stat3 is responsible for at least part of the c-met signal.
Methods: We have stably transfected a human squamous cell carcinoma (SCC) cell line (SRB12-p9) to force the
expression of a dominant negative form of Stat3 (S3DN), which we have previously shown to suppress Stat3
activity. The in vitro and in vivo malignant behavior of the S3DN cells was compared to parental and vector
transfected controls.
Results: Suppression of Stat3 activity impaired the ability of the S3DN cells to scatter upon stimulation with HGF
(c-met ligand), enhanced their adhesion, and diminished their capacity to invade in vitro and in vivo. Surprisingly,
S3DN cells also showed suppressed HGF-induced activation of c-met, and had nearly undetectable basal c-met
activity, as revealed by a phospho-specific c-met antibody. In addition, we showed that there is a strong
membrane specific localization of phospho-Stat3 in the wild type (WT) and vector transfected control (NEO4)
SRB12-p9 cells, which is lost in the S3DN cells. Finally, co-immunoprecipitation experiments revealed that S3DN
interfered with Stat3/c-met interaction.
Conclusion: These studies are the first confirm that interference with the HGF/c-met/Stat3 signaling pathway can
block tumor cell invasion in an in vivo model. We also provide novel evidence for a possible positive feedback loop
whereby Stat3 can activate c-met, and we correlate membrane localization of phospho-Stat3 with invasion in vivo.
Background
Signal transducer and activator of transcription (Stat)
proteins are a family of transcription factors that are
activated by phosphorylation of a conserved tyrosine
residue in response to a host of growth factors and
cytokines. Phosphorylated Stat dimers translocate into
the nucleus to activate of several target genes that are
involved in diverse cellular processes such as cytokine
signaling [1], cell proliferation and development [2],
abnormal tumorigenesis [3-5], and suppression of the
immune response in the tumor microenvironment [6].
Stat3, one of seven members of the Stat family, has
been most strongly implicated in tumorigenesis [3-5].
Stat3 regulated genes include cyclin D1 [7] and c-myc
[8], which are involved in cell proliferation; Bcl-XL [9],
survivin [10], and Bcl-2 [11], which mediate apoptosis;
several matrix metalloproteases involved in invasion
[12-14]; and growth factors and cytokines such as
VEGF [15] and HGF [16]. Up- or down-regulation of
many of these genes has obvious implications in the
development of cancer. Constitutive activation of Stat3
has been observed in a number of human cancers and
cancer cell lines [3]. Given that no naturally occurring
Stat3 mutations that result in constitutive activity have
been identified, the persistent Stat3 activation in
tumors is likely due to a differences in expression or
activity of proteins that regulate Stat3 or signaling
molecules involved in the Stat3 pathway. Potential can-
didates include suppressor of cytokine signaling
(SOCS), a negative regulator of cytokine signaling that
is silenced by methylation in some tumors [17,18] and
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various receptor tyrosine kinases such as EGFR and c-
met that are activated in cancers [19,20]. More recent
evidence indicates that Stat3 may be a required for the
maintenance of stem cell-like characteristics of glio-
blastoma stem cells [21]. Given the central role of
stat3 in positively effecting multiple biological pro-
cesses involved in malignant cell behavior, extensive
effort has been made to target Stat3 and suppress its
activity in cancer cells [22]. One recent preclinical
study using myeloid and B cell-specific targeting of
Stat3 by siRNA showed that silencing Stat3 expression
lead to a strong antitumor immune response [23].
Stat3 has a critical function in the development of skin
cancer [24]. Using both skin-specific Stat3 knockout
models [25,26], and a skin specific Stat3 gain of function
transgenic model (K5.Stat3C mice) [27], we have shown
in collaboration with the DiGiovanni laboratory that
Stat3 is indispensable for the initiation, promotion and
malignant progression stages of skin carcinogenesis.
More recently it has been shown, using skin stem cell-
specific knockout of Stat3, that Stat3 is required for sur-
vival of skin stem cells during tumor initiation in the
mouse skin 2-stage chemical carcinogenesis protocol,
and that it is indeed these stem cells that form the
initiated cell population that eventually gives rise to
tumors [28]. These results are reviewed in [29,30].
Malignant progression and tumor cell invasion are
often the result of uncontrolled cell motility and adhe-
sion. There is considerable evidence for a role for Stat3
signaling in cell migration and invasion under normal
and pathological situations. Overexpression and activity
of Stat3 has been linked to the invasion and metastasis
of several cancers in humans, including cutaneous squa-
mous cell carcinoma (SCC) [31,32], colorectal adenocar-
cinoma [33], and melanoma [14]. Stat3 activation is
required for induction of genes encoding matrix metal-
loproteases-1, 2, and 9 (MMP-1, MMP-2, and MMP-9)
[12-14], as well as several other genes important in the
metastatic cascade. In addition, Stat3-deficient keratino-
cytes are unable to migrate, partly due to deregulated
p130CAS phosphorylation [34], a protein which is
involved in the formation of focal adhesion complexes
and reorganization of the cytoskeleton. These studies, as
well as our studies with mouse skin-specific Stat3 gain
of function and knockout models [29,30], suggest that
Stat3 activation plays a critical role in the invasion and
metastasis of carcinomas.
Scatter factor, or hepatocyte growth factor (HGF),
can regulate cell survival, growth, migration, and
angiogenesis upon binding its cell surface receptor, c-
met [35]. c-met is often constitutively active in human
tumors [36-38], and HGF/c-met signaling is at least
partially mediated by Stat3 [20,39]. In particular, Stat3
is transiently phosphorylated after HGF treatment,
likely mediated by Stat3/c-met direct or indirect inter-
action [39]. Stat3 was coimmunoprecipitated with
phosphorylated c-met from intact cells, and the specifi-
city of this interaction was demonstrated in in vitro
competition experiments with peptides mimicking the
c-met docking sequence and Stat3 phosphorylation site
[39]. Activated Stat3 mediates signals downstream of
the HGF/c-met pathway [20], and Stat3 has been
shown to be essential for HGF-induced morphogenesis
and for invasive behavior driven by c-met in both
fibroblasts and breast carcinoma cells [39-41]. A Stat3
binding site has been identified in the HGF promoter
and this site is required for Stat3-mediated activation
of HGF transcription in breast epithelial cells [16,42].
Overall, these observations suggest that positive feed-
back signals in the HGF/c-met/Stat3 signaling pathway
could contribute to tumorigenesis.
In order to investigate the role of Stat3 in the induc-
tion of cell motility and invasion in greater detail, we
have employed a cell culture model in which a domi-
nant-negative form of Stat3 was expressed in a tumori-
genic human skin SCC cell line, SRB12-p9 [43]. Stat3a,
the full-length form of Stat3, is abundant and is consti-
tutively phosphorylated (active) in these cells. It has
been reported that Stat3b, a naturally occurring Stat3
splice variant that lacks the C-terminal transcriptional
activation domain, can act in a dominant-negative fash-
ion to inhibit the transcriptional activity of Stat3a
[44,45]. It was subsequently shown that mutating the
critical tyrosine 705 phosphorylation site to phenylala-
nine generated a form of Stat3b (Stat3b-Y705F) that
could block DNA binding by all endogenous forms of
Stat3 [46]. In this study we compare the malignant char-
acteristics of SRB12-p9 cells with that of stably trans-
fected clones that express FLAG-tagged Stat3b-Y705F
(S3DN cells), which have suppressed Stat3 activity [43].
We confirm for the first time that interference with the
HGF/c-met/Stat3 signaling pathway can block tumor
cell invasion in an in vivo model, and we present evi-
dence for a positive feedback loop between Stat3 and c-
met. Finally we correlate membrane localization of
phospho-Stat3 with invasion in vivo.
Methods
Cell culture
The human skin SCC cell line SRB12-p9 was derived by
single cell cloning from SRB-12 cells (a gift from Dr.
Janet Price, Department of Cancer Biology, University of
Texas M.D. Anderson Cancer Center). Cells were cul-
tured in a humidified atmosphere at 5% CO2, in Dulbec-
co’s Modified Eagle’s Media-F12 supplemented with 10%
fetal calf serum. Generation of the stable S3DN expres-
sing SRB12-p9 cell lines and vector control cell lines
was previously described [43].
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Invasion and scattering assays
8 μm pore-sized membrane inserts for 12 well plates
were coated with 50 μL of 1:25 diluted Matrigel base-
ment membrane matrix (Becton Dickinson) following
the manufacturer’s protocol. 25,000 WT, NEO4 and
S3DN cells were seeded in triplicate onto inserts and
incubated for 10 hours at 37°C in 5% CO2. No chemo-
attractant or serum gradient was used. After incubation,
membranes were fixed with 4% paraformaldehyde for 20
minutes and stained with hematoxylin. Cells that
migrated through the Matrigel to the bottom of the
insert were photographed on a Nikon TE300 micro-
scope and counted. For the scattering assay, cells grow-
ing in 10% FCS-containing media were treated with 100
ng/ml HGF for 24 or 48 hours and photographed with
phase contrast at 100× magnification on a Nikon TE300
microscope. Percent cell scattering was determined by
counting the total number of cells in a field (T), and the
number of cells which were visually determined to have
no cell-cell contacts (M) in the field, and applying the
following formula: percent scattering = (M/T) × 100%.
At least 6 fields were counted for each treatment group
and the fields were marked on the bottom of the dish
so that they could be located at the 24 and 48 hour
time points.
Western blotting
Cells were lysed and tumors homogenized on ice in
RIPA lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH
7.5, 1 mM EDTA, 1% NP-40, 1 mM PMSF, 1 mM Na-
orthovanadate) supplemented with 40 μl complete pro-
tease inhibitor cocktail (Roche) according to manufac-
turer-provided instructions. Extracted protein was
quantified using the BioRad Protein Assay kit. Proteins
were separated by SDS acrylamide (4-20%) gel electro-
phoresis and transferred to nitrocellulose membranes
(BioRad). Blots were blocked with 5% BSA for 1 hour at
room temperature, followed by incubation overnight at
4°C with antibodies against phosphorylated forms of c-
met (Tyr1234-1235) and Stat3 (Tyr705), total Stat3 (Cell
Signaling Technology), total c-met and b-actin (Santa
Cruz), and MMP-2 and MMP-9 (Chemicon). Blots were
washed with TBS/0.1% Tween 20 and incubated with a
horseradish peroxidase-conjugated secondary antibody
for 1 hour at room temperature, followed by an addi-
tional 3 washes with TBS/0.1% Tween 20. Chemilumi-
nescence detection was performed according to the
manufacturer’s instructions (Millipore) followed by
exposure to X-ray film or using the Chemidoc gel docu-
mentation system (BioRad).
Immunoprecipitation
After overnight incubation in serum free media, cells
were treated with 100 ng/ml HGF for 30 minutes prior
to harvest, and lysed with the following immunoprecipi-
tation buffer: 1% NP-40 in PBS with 40 μl complete
protease inhibitor cocktail (Roche), 2 mM Na-orthova-
nadate, 10 μM lactacystin, 10 mM NaF. Cell lysates (500
μg for each sample) were rocked at 4°C for 1 hour, fol-
lowed by centrifugation for 5 minutes to pellet cellular
debris. Supernatants were collected and samples were
precleared with Protein A/G Plus-Agrarose (Santa Cruz)
and normal IgG (Santa Cruz) for 1 hour at 4°C, followed
by centrifugation for 5 minutes at 20,000 g. Total Stat3
(Cell Signaling Technology) and c-met (Santa Cruz)
antibodies were added at a dilution of 1:1000 to a total
volume of 1 ml, and immunoprecipitations were per-
formed at 4°C overnight with constant rocking. 20 μl of
Protein A/G Plus-Agarose (Santa Cruz) beads were
added, and the solution was allowed to rock for 4 hours
at 4°C. Reactions were washed 3 times using immuno-
precipitation buffer and then brought up in 6× Laemli
buffer for protein electrophoresis and Western blot
analysis.
Mouse xenograft model
Groups of 6-7 week old female athymic NCR Nu/Nu
(nude) and SCID/bg mice were housed in a temperature
and humidity controlled Association for Assessment and
Accreditation of Laboratory Animal Care facility with a
12 hour light/dark cycle. All procedures were approved
by the LSUHSC Institutional Animal Care and Use
Committee in accordance with NIH guidelines. Mice
were maintained on LM-485 diet (Harlan Teklad) and
allowed access to food and water ad libitum. Mice were
injected subcutaneously in the interscapular region with
1 × 106 cells in 0.1 ml PBS. The growth of the subcuta-
neous tumors was evaluated twice weekly by caliper.
Animals were sacrificed and tumors were excised at the
end of the experiment (21 days after cell injection) and
fixed in 4% paraformaldehyde for histological observa-
tion, western blotting, and immunohistochemistry.
Immunohistochemical examination of tumors
Tumors were isolated and fixed in formalin and
embedded in paraffin prior to sectioning. Paraffin sec-
tions of 4 μm were deparaffinized in xylene, 3 × 7 min-
utes, and rehydrated by stepwise washes in decreasing
ethanol/H2O ratio (100% to 50%, followed by soaking in
water). Sections were either stained with hematoxylin
and eosin (H&E) or boiled for 1 minute for antigen
retrieval. For immunohistochemical staining, sections
were incubated in Superblock (Pierce) blocking reagent
for 1 hour at room temperature. After washing 3× in
PBS, slides were incubated for overnight at 4°C with
antibodies against p-c-met (Tyr1234-1235), p-Stat3
(Tyr705), and total Stat3 (Cell Signaling Technology),
total c-met (Santa Cruz), and MMP-2 and MMP-9
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(Chemicon). Slides were photographed on a Nikon
TE300 fluorescence microscope under oil immersion, at
600× magnification, with a CCD camera (Roper Scienti-
fic). Images were processed with IPLabs v3.55 software
(Scanalytics).
Statistical analysis
The statistical significance between experimental values
was assessed by Student’s T test. A P value of < 0.05
was considered as statistically significant.
Results
Expression of S3DN suppresses the invasion and HGF-
induced scattering of SRB12-p9 cells
In order to assess the role of Stat3 signaling in the inva-
sive potential of malignant SCC cells, we analyzed the
parental SRB12-p9 wild type (WT) and empty vector
transfected controls (NEO4), and two independent
S3DN cell lines (DN2 and DN5), in an in vitro invasion
assay. Cells were seeded onto Matrigel-coated inserts
and allowed to invade for 10 hours. Expression of S3DN
suppressed the ability of the DN2 and DN5 cells to
invade the Matrigel barrier (Figure 1A). DN2 and DN5
cells showed reduced invasion, as compared to the WT
and NEO4 cells, with an average of 99 and 114 cells per
field migrating for the DN2 and DN5 cells, as compared
to 165 and 207 cells for the WT and NEO4 cell lines,
respectively (Figure 1B). The number of invading S3DN
cells was reduced by 30-50% of that observed for WT
and NEO4. It is unlikely that these effects are due to
differences in cell survival or proliferation due to the
relatively short time course of the experiment and to
our previous studies that showed that the doubling time
and basal rate of apoptosis are the same for S3DN and
WT cells under normal culture conditions, as in this
assay [43]. It is important to note that no chemo-attrac-
tant or serum gradient was used to enhance invasion in
this experiment.
Because HGF has potent effects on the motility of
keratinocytes, and since dermal fibroblasts produce
Figure 1 Invasion and scattering of P9WT and S3DN cells in vitro. (A) 25,000 cells cultured in 10% FCS containing media were plated on
Matrigel-coated inserts and allowed to invade. Invaded cells were fixed, stained with hematoxylin, and counted. Values represent mean number
of cells for triplicate cultures. (B) Quantification of invaded cells for each cell line. Values shown are +/- SEM and P < .05 by Student’s T test for
WT/S3DN and NEO4/S3DN comparisons indicated by *. (C) Cells growing in 10% FCS-containing media were treated with 100 ng/ml HGF for 24
or 48 hours as indicated and photographed with phase contrast at 100× magnification. (D) Quantification of scattered cells expressed as percent
(of total cells) scattered per well. P < .05 by Student’s T test for WT/S3DN and NEO4/S3DN comparisons indicated by *.
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HGF in the skin [47], we decided to examine the role
of Stat3 signaling in HGF-induced motility. Cells were
allowed to grow into colonies of 8-12 cells for several
days, and then treated with 100 ng/mL human recom-
binant HGF (R&D Systems) for 24 and 48 hours.
Motility was measured as the number of cells in a
colony lacking cell-cell contact with their neighbors.
WT and NEO4 cells responded to HGF treatment
with nearly 50% of cells becoming motile by 24 hours
and maintained that status up to 48 hours later
(Figure 1C, D). However, DN2 and DN5 cells
responded minimally to HGF treatment, with only 11-
12% of total S3DN cells scattered at the 24 hour time
point (Figure 1D).
Suppression of Stat3 reduces activity of c-met in vitro:
evidence suggesting a positive feedback loop
To better understand the molecular mechanisms by
which suppression of Stat3 signaling can inhibit HGF-
induced motility, the levels of expression and activity of
c-met was determined for WT, NEO4 and S3DN cells.
Cells were treated with 100ng/ml HGF for 10 and 60
minutes and harvested after each time point. Western
blot analysis of cell lysates with phospho-specific and
total c-met antibodies revealed a decrease in the level of
phospho-c-met in DN2 and DN5 cells compared to WT
and NEO4 cells, under both untreated and HGF treated
conditions (Figure 2A, B). The reduced activity of c-met
under unstimulated conditions in the S3DN cells is
likely a result of the suppression of Stat3 signaling, sug-
gesting a positive feedback effect of Stat3 on c-met.
With HGF stimulation, the S3DN cells were unable to
induce activation of c-met to the same level as the WT
and NEO4 cells (Figure 2A, B). In fact, the sustained
activity of c-met observed in the S3DN cells at 60 min-
utes is similar to that observed in the unstimulated WT
and NEO4 cells. These results were further confirmed
by immunofluorescence analysis of WT and DN2 cells
grown in culture. The level of phospho-c-met found in
DN2 cells is diminished as compared to the WT cells,
even in the presence of HGF (Figure 2, compare WT
panels C, E and G to DN2 panels D, F and H). We
observe intense membrane localization of phospho-c-
met in WT cells treated with HGF that is absent in the
DN2 cells. Staining in cells growing at a lower con-
fluency shows a staining pattern consistent with locali-
zation in focal adhesions in both cell lines. However,
phospho-c-met specific staining is reduced in the focal
adhesions of DN2 cells (Figure 2G and 2H). No stimula-
tion of Stat3 phosphorylation above baseline levels was
observed with HGF treatment (Figure 2A, top panel).
This finding is not unexpected considering our previous
results showing that both WT and S3DN cells
have similarly high levels of constitutive Stat3
phosphorylation when grown in 10% FCS [43]. We also
showed in that study that S3DN expression, while it did
not suppress Stat3 phosphorylation, did reduce Stat3
DNA binding, indicating that Stat3 signaling was in fact
impaired in the S3DN cells [43].
S3DN inhibits the invasive potential of SCC cells in vivo
To compare the in vivo tumorigenic potential of WT,
NEO4 and S3DN cells, we used two immuno-compro-
mised mouse tumorigenicity model systems. Both nude
and SCID mice were injected subcutaneously on their
dorsal side with 1 × 106 cells suspended in 100 μl of
sterile PBS. Interestingly, expression of S3DN did not
reduce total tumor volume, nor did it affect tumor
growth kinetics, as had been predicted (Figure 3A, left
panels and data not shown). However, closer examina-
tion of the tumors upon harvest revealed differences in
tumor behavior that we segregated into three groups:
non-invasive, for tumors that were encapsulated and
easily removed from the body wall; attached, for tumors
that had some superficial growth onto the muscle of the
body cavity; and invasive, for tumors that showed com-
plete invasion into the muscle and often had to be
excised with muscle or bone together. Macroscopic
examination revealed that the WT and NEO4 tumors
were more often strongly attached to the musculature of
the body wall, and in many cases were found to be
invading into the muscle (Figure 3A, right panels, 3B).
This was in contrast to the S3DN tumor group in which
most tumors where either well encapsulated or easily
removed from the underlying muscle (Figure 3A, lower
right, 3B). In fact, only 18-20% of the tumors arising
from the S3DN cells grew attached to the musculature
or invaded into the body cavity, compared to 50-80% of
the WT and NEO4 tumors (Figure 3B). The distribution
of tumor phenotypes comparing WT to NEO4 cells was
not statistically significantly different, with the 2-sided
probability, p ≤ 0.261, using the Fisher’s exact test. Simi-
larly, the tumor phenotype distribution comparing DN2
to DN5 cells was not different (p ≤ 0.764). When com-
paring the tumor phenotype distribution of WT and
NEO cells combined, with that of DN2 and DN5 cells
combined, the difference was highly statistically signifi-
cant (p ≤ 0.0006). There were no differences in the effi-
ciency of tumor establishment, with all cell lines
producing single tumors in the mice.
Expression of S3DN alters the localization of active Stat3
in the cell
Since S3DN expression correlated with suppression of
tumor invasion, we sought to determine whether it
altered the levels or subcellular localization of active
Stat3 in tumors. Stat3 activity is maintained in tumors
arising from WT, NEO4 and S3DN cells, as determined
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by immunohistochemical staining with a Tyr705 phos-
phorylation site-specific antibody for Stat3 (Figure 4A,
upper panels). There was also no observable difference
in total Stat3 expression between WT, NEO4 and S3DN
tumors, where the majority of bulk protein expression
was observed in the cytoplasm (Figure 4A, lower panels,
compare WT and NEO4 to DN2 and DN5). However,
the subcellular localization of active Stat3 differed
between the two groups of tumors. The DN2 and DN5
tumors expressed pTyr705 Stat3 primarily in the nuclei,
which is the expected localization for activated Stat3
(Figure 4A, DN2 and DN5 panels). The WT and NEO4
tumors had nuclear expression of p-Tyr705 Stat3, but
also showed strong staining localized to the cell mem-
brane, particularly in the larger cells in squamous cen-
ters (Figure 4A, upper panels, compare WT and NEO4
to DN2 and DN5). This finding is consistent with our
recent results in human skin SCC, where we found both
prominent nuclear staining of p-Tyr705 Stat3 as well as
membrane-specific staining in centers of squamous dif-
ferentiation [48]. Total levels of Stat3 activity and
expression were determined by Western blot analysis of
tumor lysates. We found that, like the immunostaining
results, there was no quantitative difference in the levels
of either phospho-Stat3 (p-Tyr705 Stat3), which detects
both the Stat3a and Stat3b bands, or total Stat3
Figure 2 Analysis of HGF-induced c-met activity in cell lines. (A) WT, NEO4 and S3DN cells were stimulated with 100 ng/mL HGF for 10 and
60 minutes. Lysates were resolved on a 4-20% SDS polyacrylamide gel, transferred to nitrocellulose, and probed sequentially with antibodies for
p-Stat3, total Stat3, p-c-met, total c-met, and b-actin. (B) Bar graph of western blot quantification. Values indicate the scanned signals normalized
to the b-actin signal. (-) and (+) correspond to without and with HGF treatment, respectively. (C) WT & DN2 cells were stimulated with 100 ng/
mL HGF for 30 minutes and probed with a p-c-met antibody, followed by an Alexa-546 tagged secondary antibody. Panels photographed at
600×. Arrows in C, lower panels indicate focal adhesion staining.
Syed et al. BMC Cancer 2011, 11:180
http://www.biomedcentral.com/1471-2407/11/180
Page 6 of 11
expression (T-Stat3) (Figure 4B). We note that in spite
of the lack of reduction of nuclear phospho-Stat3 in the
S3DN cells, Stat3 activity in these cells is reduced. We
previously showed that S3DN cells have reduced Stat3
DNA binding as measured by EMSA [43], verifying the
suppressive effect of S3DN expression on Stat3 activity.
S3DN reduces expression of MMP-2 and MMP-9, and
inhibits c-met phosphorylation in vivo
We next determined the expression levels of MMP-2
and MMP-9, two key matrix metalloproteases involved
in the degradation of the basement membrane, and fre-
quently upregulated in invading tumor cells. Both
MMP-2 and MMP-9 are transcriptional targets of Stat3
[12,14]. Immunostaining and Western blotting revealed
that MMP-2 and MMP-9 expression was reduced in
DN2 tumors compared to WT tumors, (Figure 5A, com-
pare upper left panels lower left panels, 5B,C). Dimin-
ished matrix metalloprotease expression is one of the
Figure 3 In vivo tumorigenicity potential of P9WT and S3DN
cells. (A) Nude and SCID mice were injected with WT and DN2 cells
and tumors were assessed by immunohistochemical analysis. H&E
stained paraffin sections of tumors generated from WT and DN2
cells were photographed at 100×. T (tumor) and M (muscle)
indicate invasive growth of P9WT cells. (B) Tumor invasion bar
graph. Tumors were designated as non-invasive, attached, or
invasive and expressed as a percent of total tumors. * The 2-sided
probability (p) ≤ 0.0006 comparing the tumor phenotype
distribution of WT and NEO cells combined, with that of DN2 and
DN5 cells combined.
Figure 4 Immunohistochemical staining of p-Tyr705 Stat3 and
total Stat3 (T-Stat3) and localization in WT, NEO4 and S3DN
tumors. (A) Paraffin sections of tumors in SCID mice were probed
with p-Tyr705 Stat3 and T-Stat3 antibodies, followed by an Alexa
546-labeled secondary antibody. Panels were photographed at
600×. (B) Lysates pooled from WT and DN2 tumors were resolved
on a 4-20% SDS polyacrylamide gel, transferred to nitrocellulose,
and probed with antibodies for p-Tyr705 Stat3, T-Stat3, and b-actin.
Scale bar: 50 μM.
Figure 5 Expression of tumor markers in WT and DN2 tumors.
(A) Paraffin sections of tumors generated from WT and DN2 cells
were probed with MMP-2, MMP-9, p-c-met, and total c-met
antibodies, followed by an Alexa 546-labeled secondary antibody.
Panels were photographed at 600×. (B) Lysates generated from WT
and DN2 tumors were resolved on a 4-20% SDS polyacrylamide gel,
transferred to nitrocellulose, and probed sequentially with
antibodies for p-c-met, total c-met, MMP-2, MMP-9, and b-actin. (C)
Bar graph of western blot quantification.
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likely causes of the reduction in observed invasion in
S3DN tumors. Gelatin zymography of conditioned
media harvested from WT, NEO4 and S3DN cells also
indicated that MMP-2 and MMP-9 activity is reduced in
S3DN cells (data not shown).
Immunostaining and Western blot analysis of tumors
for expression of phospho-c-met agreed with our in
vitro results (Figure 2), where we also noted reduced
phospho-c-met expression in DN2 tumors compared to
WT (Figure 5, compare p-c-met panel to lower p-c-met
panel, 5B,C). In fact, the intense membrane-specific
localization, typical of activated c-met, that was observed
in the WT tumors was absent in the DN2 tumors.
Unexpectedly, we found that unlike in S3DN cells
grown in culture, total c-met levels were diminished in
DN2 tumors compared to WT (Figure 5A, far right
panels, 5B,C).
S3DN interferes with c-met/Stat3 interaction
In an attempt to better understand the c-met/Stat3 inter-
action in this model, we analyzed the binding interaction
between c-met and Stat3 in S3DN cells. It is possible that
the reduced basal and HGF-inducible c-met activity in
S3DN cells correlates with reduced c-met/Stat3 interac-
tion. We used antibodies for total c-met and Stat3 for
reciprocal immunoprecipitation experiments with WT
and DN2 cells treated with HGF. We detected an interac-
tion between c-met and Stat3, which was enhanced with
HGF treatment in the WT but not DN2 cells (Figure 6,
upper panel WT lanes). This level of interaction was
lower in the DN2 cells compared to WT (Figure 6, top
panel and third panel, compare WT lanes to DN2).
These results suggest that a possible HGF/c-met/Stat3
positive feedback loop that is hyperstimulated in WT
cells is at least partially suppressed with expression of
S3DN.
Discussion
Given the cumulative evidence supporting Stat3 as a
potential therapeutic target in cancer and that there
are ongoing clinical trials testing Stat3 inhibitors [49],
our group has attempted to better understand the
molecular mechanisms of Stat3 activity and the role of
HGF/c-met in transducing its signal. To this aim, we
have used the S3DN system, which provides a work-
able cell culture model to study multiple aspects of
Stat3 function in detail. Here we successfully demon-
strate that even partial reduction in Stat3 activity is
sufficient to restrict motility and invasion. S3DN (DN2
and DN5) cells were significantly less invasive in both
in vitro and in vivo assays, and this phenotype was
accompanied by marked suppression of MMP-2 and
MMP-9 expression, c-met activity, as well as inhibition
of Stat3/c-met interaction.
The expression of S3DN reduced HGF-induced scat-
tering and invasion through Matrigel-coated membranes
(Figure 1). This assay indicates that the motile pheno-
type of the P9WT cells in this context is cytokine
dependent and mediated by Stat3, which is relevant for
tumors growing in vivo where they respond to a variety
of cytokines and growth factors from host cells or from
autocrine stimulation. The lack of complete suppression
of invasiveness for the S3DN tumors indicates less than
full penetrance for the effect of S3DN expression. This
can be attributed to the fact that there is still active
Stat3 in the S3DN cells (Figure 4, data not shown). It is
also possible that the percentage of attached and inva-
sive tumors would have been even higher for the WT
and NEO4 groups had the experiment been carried out
for a longer time, since it is likely that those tumors
designated as attached would have eventually become
invasive if allowed to grow longer.
We originally hypothesized that the mechanism for
the reduced invasive behavior of S3DN cells is due to a
suppression of c-met-mediated events. c-met is fre-
quently constitutively active in human tumors [36-38],
and several reports have shown that Stat3 is one of the
downstream effectors of HGF/c-met signaling [20,39].
HGF treatment enhances Stat3 activity, likely due to an
Figure 6 Coimmunoprecipitation of Stat3/c-met. WT and DN2
cells treated with 100 ng/ml HGF for 30 minutes and untreated
controls were immunoprecipitated with total c-met and Stat3
antibodies. Western blot analysis of immunoprecipitates with
reciprocal antibodies shows interaction between Stat3 and c-met,
which is diminished in DN2 cells. Whole cell lysates probed with
total Stat3 and c-met antibodies shown as loading control. IgG
controls indicate the use of rabbit IgG instead of antibodies to c-
met or Stat3 for the immunoprecipitations.
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interaction between c-met and Stat3 [39]. We show that
expression of S3DN leads to reduced baseline as well as
inducible c-met activity in S3DN cells and tumors (Fig-
ure 2, 4). Inhibition of c-met activity in S3DN cells is
also associated with reduced localization of p-c-met to
focal adhesions (Figure 2). These findings provide a
strong indication for a positive feedback loop involving
HGF, c-met, and Stat3. The existence of such a feedback
loop is further supported by our finding that S3DN cells
are less responsive to HGF-induced motility. An analysis
of the levels of endogenous HGF secretion in S3DN
cells by ELISA revealed no detectable difference between
the WT, NEO4 and S3DN cell lines (data not shown).
However, the levels of secreted HGF in these cells were
difficult to compare since they were below the detection
threshold of the ELISA (< 40 pg/ml). We note that
based on numerous reports concerning the biological
effects of HGF, which typically fall in the ED50 range of
20-100 ng/ml, we do not expect that these cells produce
sufficient amounts of HGF to ellicit an autocrine
response. Our initial hypothesis was supported by our
finding that there was an interaction between Stat3 and
c-met proteins, and that this interaction is reduced in
cells that express S3DN (Figure 6). It is possible that
Stat3/c-met interaction occurs through FAK, since there
are known associations between c-met and FAK [50]
and Stat3 and FAK [51]. We did find an association
between c-met and FAK in IP experiments, but there
was no detectable difference in the degree of this inter-
action between WT and S3DN cells (data not shown).
We speculate that S3DN is preventing the activation of
c-met at the cell membrane by interfering with normal
Stat3/c-met interaction, possibly by competing with
Stat3 for binding to c-met.
Interestingly, we observed membrane localization of p-
Stat3 (Tyr705) in WT and NEO4 tumors, but not in the
S3DN tumors, which had only nuclear staining (Figure
4A). This is in line with our previously published results
with human SCC samples where we observed p-Stat3
(Tyr705) staining at the cell membrane and nuclei in
tumors, but only in nuclei in the immediately adjacent
non-malignant skin [48]. It is possible that the mem-
brane localization of p-Stat3 (Tyr705) is specific to cells
that are more malignant. Recent published reports indi-
cate that there are potential non-nuclear functions for
Stat3. The functional flexibility of Stat3 was outlined in
a review published by Gao and Bromberg [52], specifi-
cally describing a non-transcriptional, cytoplasmic role
that may potentiate cell motility. A Stat3-stathmin inter-
action has been documented [53], as well as Stat3 locali-
zation at focal adhesions with FAK and paxillin [51]. A
recent publication describes a metabolic function in the
mitochondria that supports Ras-dependent transforma-
tion [54] and cellular respiration [55]. These reports
indicate non-nuclear roles for Stat3 that contribute to
the oncogenic properties of cancer cells and that these
functions are separate from tyrosine-phosphorylation
dependent transcriptional activity. We provide further
support for a novel function for Stat3 by describing
invasive tumors with a distinct Stat3 membrane localiza-
tion. Although we do see suppression of MMP-2 and
MMP-9 expression, which is likely due to transcriptional
downregulation caused by S3DN expression, we propose
that Stat3 may also be acting at the membrane to
enhance motility and invasion (Figure 6). We further
speculate that the Stat3 protein engaged in the non-
transcriptional function at the membrane may be exert-
ing a fast-acting response to external activators, whereas
the transcriptional activation of genes like the MMPs by
nuclear Stat3 could be a slower mechanism to potentiate
cell motility. Thus, it is possible that the transcriptional
and non-transcriptional functions of Stat3 are working
in concert to influence cell migration, especially in
malignant, invasive cells.
The lack of diminished phospho-Stat3 staining in the
S3DN cells appears at first contradictory to previous
data showing a positive correlation between Stat3 phos-
phorylation and activity. However we suggest that the
S3DN protein blocks endogenous Stat3 activity at a
point downstream of its phosphorylation. We have pre-
viously shown that Stat3 DNA binding, as measured by
EMSA, is reduced in the S3DN cells compared to WT
cells, confirming that S3DN expression has a suppres-
sive effect on Stat3 activity [43].
Our observation that S3DN tumors grew to similar
size as WT and NEO4 tumors was unexpected. A pre-
vious report, using HT-29 colon carcinoma cells in
mouse xenograft experiments, showed a reduction in
tumor size for cells stably expressing a similar Stat3
dominant negative form compared to parental HT-29
tumors [56]. One possible explanation for this discre-
pency could be the fact that the parental HT-29 cells,
unlike the SRB12-p9 cells, were negative for constitu-
tive activation of Stat3 in the absence of exogenously
added growth factors. From our initial studies of the
S3DN cells we observed that the proliferation rate was
unaffected by S3DN expression in vitro, while sensitiv-
ity to exogenous growth factor deprivation was
increased [43]. We hypothesized that the partial sup-
pression of Stat3 activity in the S3DN cells was suffi-
cient to affect survival under growth factor deprived
conditions, but not sufficient to affect proliferation
rate. In the case of HT-29 cells, where dominant nega-
tive Stat3 expression appears to completely block Stat3
activity[56], the tumor size is reduced even though
host supplied growth factors are present. To observe a
similar effect in our system would likely require stron-
ger suppression of Stat3 activity.
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Conclusions
We have shown for the first time in an in vivo tumor
model that the HGF/c-met/Stat3 signaling cascade is cri-
tically involved in the motility and invasion of cancer
cells, and disruption of this pathway by expression of
S3DN suppresses invasion, reduces c-met activity and
inhibits c-met/Stat3 interaction. Tumor cells producing
high levels of HGF can activate c-met by either autocrine
or paracrine signaling mechanisms, which leads to Stat3
activation and gene transcription. Based on the indica-
tions for a positive feedback loop between c-met and
Stat3, we speculate that abnormally high levels of c-met
activation could trigger this loop and drive cells toward
invasive behavior. We also show that there is a possible
role for Stat3 at the cell membrane that contributes to
the malignant phenotype of invading tumor cells. We
must express a high degree of caution in generalizing
these results to all tumor cell types or even to other skin
SCC cells, since these findings are confined to a single
cell line. It will be necessary to perform a similar series of
experiments on other skin SCC cell lines, as well as other
tumor cell types. Attempts to generate additional stably
expressing S3DN cells using other skin-derived cell lines,
and cell lines of other tumor types, have been unsuccess-
ful so far. This is perhaps due to a S3DN-mediated sup-
pression of proliferation and/or survival that is too strong
in those cells. The SRB12-p9 cells are likely to be unique
in having a very strong constitutive Stat3 activity when
grown in the presence of serum, thereby allowing survival
of stable S3DN clones. Never-the-less, based on these
results we suggest that targeting the HGF/c-met/Stat3
pathway could be an especially effective strategy for can-
cer therapy. Future work will focus on exploring the
interaction between Stat3 and c-met, and the relationship
of the HGF/c-met/Stat3 signaling loop to the invasive
potential of skin SCC cells.
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